Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
12. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136—2141.
13. Roberts WL, Sedrick R, Moulton L, et al. Evaluation of four automated high-sensitive C-reactive protein methods; implications for clinical and epidemiological applications. Clin Chem 2000; 46: 461—468.
14. Александрова ЕН, Новиков АА, Насонов ЕЛ. Высокочувствительные методы определения С-реактивного белка (обзор). Принята к печати.
15. Ockene IS, Mathews CD, Rifai N, et al. Validity and classification accuracy of serial highsensitive C-reactive protein measurements in healthy adults. Clin Chem 2001; 47: 444—450.
16. Насонов ЕЛ. Маркеры воспаления и атеросклероз: значение С-реактивного белка. Кардиология, 1999; 2: 81—85.
17. Насонов ЕЛ, Панюкова Е.В, Александрова ЕН. С-реактивный белок — маркер воспаления при атеросклерозе (новые данные). Кардиология, 2002; 42: 53—60.
18. Ridker PM. Clinical application of C-reac-tive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363— 369.
19. Mendall MA, Strachman DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular
SHS-OOO4.qxd 21.11.2006 16:56 Page 294
Насонов Е.Л. Антифосфолипидный синдром.
risk factors in man. Eur Heart J 2000; 21: 1584—1590.
20. Koening W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predict future risk of coronary heart disease in initially healthy middle-aged men. Results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort study, 1984 to 1992. Circulation 1999; 99: 237—242.
21. Ridker P, Hennekens C, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836—843.
22. Ridker P, Rifai N, Clearfield M et al. Measurement of C-reactive protein for the targering of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959—1965.
23. Ridker PM, Stampfer MJ, Rifai N. Novel riskfactorsforsystemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocys-tein, lipoprotein(a), and standart cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481—2485.
24. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Atheroscler Thromb Vasc Biol 1997; 17: 1121—1127.
25. Danesh J, Whincup PM, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analy-sis. Br Med J 2000; 321: 199—204.
26. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 336: 973—979.
27. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of inter-leukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767—1772.
28. Albert MA, Danielson E, Rifai N, et al. Effects of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation
(PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64—70.
29. Kuller LH, Tracy RP, Shaten J, et al. for MRFIT research group. Relationship of C-reac-tive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996; 144:537—547.
30. Biasucci L., Liuzzo G., Grillo R., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855—860.
31. Haverkate F, Thompson SG., Pyke SDM, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462—466.
32. Heescheh C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and tro-ponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeriv c7E3 AntiPlatelet Therapy in Unstable angina Refractory to standart treatment trial. J Am Coll Cardiol 2000; 35: 1535—1542.
33. Mueller C, Buettner HJ, Hodgson KM, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105: 1412— 1415.
34. Sakkinen P, Abbott RD, Curd JD, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55: 445—451.
35. Zebrak JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitive C-reactive protein in predictive long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002; 89: 145—149.
36. Winbeck K, Popper H, Etgen T, et al. Prognostic relevance of early serial C-reactive protein measurement after first ischemic stroke. Stroke 2002; 33: 2459—2464.
